Clinical trials: Neuroendocrine Tumors, NET
Neuroendocrine Tumors, Gep Net
Observational Study on GEP-and Pulm-NET Treated at FPG
Observational ambispective monocentric study on the clinical, laboratory, pathological and molecular characteristics of patients suffering from gastroenteropancreatic tract and pulmonary neuroendocrine tumors and their prognostic…
- Conditions
- Neuroendocrine Tumors, Gep Net, Pulmonary Neuroendocrine Neoplasm
- Trial name
- ETNA-FPG (NCT06402695)
- Where
- Italy
- Volunteers
- 650 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuroendocrine Tumors, Von Hippel-Lindau Syndrome
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Background: Neuroendocrine tumors (NETs) are rare but have been more common over the past decade. The only treatment for NETs is surgery, but most are found when they are too advanced for surgery.
- Conditions
- Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease
- Trial name
- NCT01967537
- Testing
- 68Gallium DOTATATE, Radio-guided surgery
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Neuroendocrine Tumor (NET)
Nutrition Intervention for Pancreatic Cancer
Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due to exocrine pancreatic insufficiency (EPI) and leads to…
- Trial name
- NCT07554560
- Testing
- Structured Lipid Medical Food
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's Hospital of Philadelphia
Neuroendocrine Tumors
68Ga-DOTA-TATE PET/CT Imaging in NETs
This clinical trial is a pragmatic study aiming to evaluate the innocuity/safety profile of the PET radiotracer 68Ga-DOTA-TATE, and to establish the procedure as a routine standard-of-care diagnostic tool for all neuro-endocrine…
- Trial name
- NCT04847505
- Testing
- 68Ga-DOTA-TATE
- Where
- 2 sites in Canada
- Volunteers
- 5,000 people
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Neuroendocrine Neoplasm
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Sintilimab combined with IBI310 and Surufatinib for the treatment of high-grade advanced-neuroendocrine neoplasm
- Trial name
- NESSIE (NCT05165407)
- Testing
- Sintilimab, IBI310, Surufatinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Peking University
Gastro-Enteropancreatic Neuroendocrine Tumor
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to detect and localize gastro-entero-pancreatic…
- Trial name
- NCT03220217
- Testing
- Satoreotide trizoxetan 5-20μg, Satoreotide trizoxetan 30-45μg
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 29 people
- Sponsor
- Ipsen
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB
Tumor-associated Hyperinsulinism (Tumor HI)
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
This expanded access program is intended to provide ersodetug, an investigational drug, to eligible participants who suffer from inadequately controlled hypoglycemia due to tumor-associated hyperinsulinism and are unable to…
- Trial name
- NCT07262970
- Testing
- Ersodetug (9 mg/kg) + SOC
- Where
- United States
- Sponsor
- Rezolute
Small-cell Lung Cancer, Neuroendocrine Carcinoma
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
This is a non-randomized single-arm, two cohorts, phase II study of iadademstat in combination with weekly paclitaxel in patients with relapse/refractory SCLC or extrapulmonary G3 Neuroendocrine Carcinomas.
- Trial name
- NCT05420636
- Testing
- Iadademstat, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
Gastroenteropancreatic Neuroendocrine Tumors
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post…
- Trial name
- NCT04524442
- Testing
- arginine/lysine
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 42 people
- Sponsor
- Advanced Accelerator Applications
Pancreatic Surgery
Pancreatectomy for NET: External Evaluation of WHO 2017 Grading System
Aim: The aim of this study was to investigate the clinicopathological factors and to evaluate the prognostic accuracy of the new World Health Organization (WHO) 2017 grading system in pancreatic neuroendocrine tumor (PanNET)…
- Trial name
- PanTEN (NCT03791346)
- Where
- France
- Volunteers
- 138 people
- Sponsor
- University Hospital, Montpellier
Neuroendocrine Tumors
Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study
Patients with gastroenteropancreatic neuroendocrine tumours (NET) often die from intrahepatic disease or are excluded from liver-directed treatment because of extrahepatic disease.
- Trial name
- HEPAR_Plus (NCT02067988)
- Testing
- Holmium-166 microspheres hepatic radioembolization.
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- UMC Utrecht
Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Conditions
- Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
- Trial name
- NCT03600233
- Testing
- CVM-1118
- Where
- 8 sites in Taiwan
- Volunteers
- 34 people
- Sponsor
- TaiRx, Inc.
Tumor Hyperinsulinism (Tumor HI)
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
- Trial name
- Tumor HI (NCT06881992)
- Testing
- Ersodetug
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 16 people
- Sponsor
- Rezolute
Neuroendocrine Tumors, Carcinoma, Small Cell Lung
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocrine tumors or small cell lung…
- Conditions
- Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
- Trial name
- NCT02936323
- Testing
- PEN-221
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 89 people
- Sponsor
- Tarveda Therapeutics
Pulmonary Neuroendocrine Tumor
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
The goal of this clinical trial is to investigate if chemotherapy works with surufatinib to treat pulmonary neuroendocrine tumors. It will also learn about the safety of this combination regimen.
- Trial name
- NCT07357623
- Testing
- Surufatinib Combined With Standard chemotherapy, Surufatinib
- Where
- 4 sites in China
- Volunteers
- 96 people
- Sponsor
- Shanghai Chest Hospital
Neuroendocrine Tumor, Gastrointestinal Neoplasm
A Study of XmAb®18087 in Subjects With NET and GIST
This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK…
- Trial name
- NCT03411915
- Testing
- XmAb18087
- Where
- 16 sites in United States
- Volunteers
- 62 people
- Sponsor
- Xencor, Inc.
Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib in patients who have…
- Conditions
- Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
- Trial name
- NCT05773274
- Testing
- Biospecimen Collection, Cabozantinib, Computed Tomography
- Where
- 42 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Gastroenteropancreatic Neuroendocrine Tumors
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
This study is for patients with non-resectable, recurrent, or metastatic well or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- Trial name
- PLANET (NCT03043664)
- Testing
- Lanreotide, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Duke University
Neuroendocrine Tumors, NET
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with…
- Conditions
- Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NCT05997056
- Testing
- nab-sirolimus
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aadi Bioscience, Inc.